Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Satellos Bioscience Inc. (T.MSL) had Consolidated Net Income/Loss of -16.22M for the most recently reported fiscal quarter, ending 2026-06-30.
| Income Statement Financials | |
-- |
|
-16.22M |
|
-- |
|
-- |
|
-- |
|
-16.84M |
|
-- |
|
-16.16M |
|
-16.16M |
|
-16.22M |
|
-16.22M |
|
|
Consolidated Net Income/Loss |
-16.22M |
-16.22M |
|
-16.84M |
|
-16.84M |
|
20.83M |
|
20.83M |
|
-0.78 |
|
-0.78 |
|
| Balance Sheet Financials | |
-- |
|
-- |
|
-- |
|
91.06M |
|
-- |
|
-- |
|
-- |
|
8.12M |
|
82.95M |
|
82.95M |
|
82.95M |
|
20.84M |
|
| Cash Flow Statement Financials | |
-24.39M |
|
-50.78M |
|
71.91M |
|
13.57M |
|
10.24M |
|
-3.34M |
|
2.28M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
11.22 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-24.39M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-19.56% |
|
-19.56% |
|
-17.82% |
|
-19.56% |
|
3.98 |
|
-1.17 |
|
-1.17 |
|